title: Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).
abstract: In genetic male fetuses, dihydrotestosterone (DHT) plays an important role in normal prostatic and external genital differentiation. The enzyme steroid 5-alpha reductase (5 alpha R) catalyzes the conversion of testosterone (T) to DHT. The importance of 5 alpha R in sexual differentiation is evident from the study of human genetic males who congenitally lack this enzyme and consequently develop ambiguous genitalia. These individuals are specifically deficient in the type 2 isozyme, whereas the normal type 1 isozyme activity has been found. The purpose of this study was to determine 1) the suitability of the rhesus monkey for testing the safety of 5 alpha R inhibitors when administered during pregnancy and 2) the potential risk of administering a known type 2 5 alpha R inhibitor, finasteride, during the critical period of internal and external genital differentiation in rhesus monkeys. In vitro studies were also performed on selected rhesus monkey tissues to determine the distribution of the 5 alpha R isozymes. Gravid monkeys were treated once daily from gestational days (GD) 20 to 100. Sonographic monitoring was performed during the course of gestation to monitor viability, growth, and organ system development. Detailed fetal evaluations for developmental abnormalities were performed at term (GD 152 +/- 2). A group of 13 pregnant monkeys ("positive control") were given a high oral dose (2 mg/kg/day) of finasteride to demonstrate that inhibiting type 2 5 alpha R results in specific external genital abnormalities in male fetuses. Thirty-two pregnant monkeys were administered an intravenous (i.v.) formulation of finasteride at doses of 8, 80, or 800 ng/day. The highest i.v. dose selected was at least 60-750 times the semen levels of finasteride in man given orally 5 or 1 mg/day, respectively. Seventeen vehicle-control pregnant monkeys were also included. Administration of a high oral dose (2 mg/kg/day) of finasteride resulted in external genital abnormalities characterized by hypospadias, preputial adhesions to the glans, a small underdeveloped scrotum, a small penis, and a prominent midline raphe in male fetuses; however, no developmental abnormalities were seen in female fetuses. Similarly, no abnormalities were observed in either male or female fetuses of mothers given iv doses (8, 80, or 800 ng/day) of finasteride during pregnancy. The in utero sonographic findings in fetuses correlated with the gross findings at term. These studies have shown that external genital abnormalities can be produced in male monkey fetuses when exposed to a high oral dose (2 mg/kg/day) of finasteride, whereas no abnormalities were observed in fetuses exposed to the i.v. formulation of finasteride. Detailed in vitro studies demonstrated that the rhesus monkey also has two 5 alpha R isozymes (types 1 and 2) with a tissue distribution similar to that seen in man and, furthermore, that finasteride is a potent, mechanism-based inhibitor with selectivity for both human and rhesus type 2 5 alpha R. These studies have demonstrated that the monkey is a suitable model for assessing the safety of 5 alpha R inhibitors administered during pregnancy.
authors.affiliation: Department of Safety Assessment, Merck Research Laboratory, West Point, Pennsylvania 19486, USA.
authors.forename: S
authors.initials: S
authors.lastname: Prahalada
authors.forename: A F
authors.initials: AF
authors.lastname: Tarantal
authors.forename: G S
authors.initials: GS
authors.lastname: Harris
authors.forename: K P
authors.initials: KP
authors.lastname: Ellsworth
authors.forename: A P
authors.initials: AP
authors.lastname: Clarke
authors.forename: G L
authors.initials: GL
authors.lastname: Skiles
authors.forename: K I
authors.initials: KI
authors.lastname: MacKenzie
authors.forename: L F
authors.initials: LF
authors.lastname: Kruk
authors.forename: D S
authors.initials: DS
authors.lastname: Ablin
authors.forename: M A
authors.initials: MA
authors.lastname: Cukierski
authors.forename: C P
authors.initials: CP
authors.lastname: Peter
authors.forename: M J
authors.initials: MJ
authors.lastname: vanZwieten
authors.forename: A G
authors.initials: AG
authors.lastname: Hendrickx
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism; D058891:5-alpha Reductase Inhibitors; D000014:Abnormalities, Drug-Induced / Q000000981:diagnostic imaging / Q000209:etiology*; D000818:Animals; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000097:blood / Q000633:toxicity*; D005260:Female; D018120:Finasteride / Q000097:blood / Q000633:toxicity*; D005837:Genitalia, Male / Q000002:abnormalities* / Q000000981:diagnostic imaging; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011467:Prostate / Q000201:enzymology; D012449:Safety; D012733:Sex Differentiation / Q000187:drug effects; D014463:Ultrasonography
chemical_list: D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D018120:Finasteride; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase